The easy deployment and safety features of the MYNX ACE® device help ensure proper use for a consistent close1
1TPR8333-02.A Usability Verification and Validation Test Report – Mynx Ace (MX6740)
The MYNX ACE® device is the latest addition to the MYNX® product family. Combining the reliability of an easy to use deployment system with the security of mechanical closure and safety of an extravascular sealant, the MYNX ACE® device provides closure you can count on.
The GRIP™ sealant securely adheres to the arteriotomy and dissolves within 30 days, leaving nothing permanently behind but a healed artery. All MYNX® devices achieve hemostasis without cinching, clamping or suturing, helping to provide a gentle closure for the patient.
Position the device with a semi-compliant balloon to gain temporary hemostasis.
Place the sealant gently with no cinching, sutures or metal implants.
Remove the device and leave nothing behind but a healed artery. The sealant resorbs within 30 days.
The MYNX ACE® Vascular Closure Device
Rajesh M. Dave, MD. Endovascular Today. February 2015
Successful Reduction of Surgeries Secondary to Arterial Access Site Complications
A Retrospective Review at a Single-Center with an Extravascular Closure Device.
Noor S, Meyers S, Curl R. Vasc Endovascular Surg. 2010;44(5):345-9.*
A Prospective Randomized Single-blind trial of Patient Comfort Following Vessel Closure
Extravascular Synthetic Sealant Closure Provides Less Pain than a Self-tightening Suture Vascular Compression Device. Fargen KM, Hoh BL, Mocco J. J Neurointerv Surg. 2011;3(3):219-23
Mynx Vascular Closure Device Early Ambulation Study
Vikranth R. Gongidi, DO; Ahsan Jafir, DO; and Vijay Verma, MD, FACC, FSCAI. Endovascular Today. October 2013
Occurrence of angiographic femoral artery complications after vascular closure with Mynx and AngioSeal
Fargen KM, Velat GJ, Lawson MF, et al. J Neurointerv Surg. 2013;5(2):161-4
Use of Vascular Closure Device After Access of Common Femoral Artery Through an Existing Stent
George JC. Vascular Disease Management. May 2012;9(5):E68-E70.
Two Years of Extravascular Closure With the Mynx® Vascular Closure Device
The Baptist Memorial Hospital experience revisited. David Wolford, MD, FACC. Endovascular Today. August 2010.
Mynx Closure in a Patient Treated for Chronic Total Occlusion of the Iliac Artery with Multiple Sheath Exchanges.
A Case Review. Michael S. Fenster, MD. TCTMD. May 2009.
Why Extravascular Closure?
The Baptist Memorial Hospital Experience with the Mynx Vascular Closure Device
David Wolford, MD, FACC. Endovascular Today. August 2009.
The Safety and Efficacy of an Extravascular, Water-Soluble Sealant for Vascular Closure
Initial Clinical Results for Mynx. D. Scheinert MD et al. Catheterization and Cardiovascular Interventions. October 2007
In the United States, fax your order to 877.933.0133, email GMB-ACI-Customer-Service@cardinalhealth.com, or call 877.700.6969. Outside of the United States, contact your local MYNX® device distributor.
The MYNX ACE® Vascular Closure Device includes:
MYNX ACE® Vascular Closure Device